NeoGenomics, Inc. (NEO) Given Average Recommendation of “Buy” by Brokerages

Shares of NeoGenomics, Inc. (NASDAQ:NEO) have received a consensus recommendation of “Buy” from the fourteen analysts that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation, nine have issued a buy recommendation and three have assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $20.00.

Several equities analysts recently issued reports on the stock. BidaskClub upgraded shares of NeoGenomics from a “buy” rating to a “strong-buy” rating in a report on Saturday, October 27th. Zacks Investment Research lowered shares of NeoGenomics from a “hold” rating to a “sell” rating in a report on Thursday, July 19th. Benchmark set a $22.00 target price on shares of NeoGenomics and gave the company a “buy” rating in a report on Thursday. Raymond James boosted their target price on shares of NeoGenomics from $16.00 to $21.00 and gave the company a “buy” rating in a report on Wednesday. Finally, First Analysis set a $16.00 target price on shares of NeoGenomics and gave the company a “buy” rating in a report on Tuesday, September 18th.

Institutional investors and hedge funds have recently bought and sold shares of the business. PNC Financial Services Group Inc. bought a new stake in NeoGenomics in the second quarter valued at $272,000. BlackRock Inc. increased its stake in NeoGenomics by 0.3% in the first quarter. BlackRock Inc. now owns 3,964,943 shares of the medical research company’s stock valued at $32,354,000 after purchasing an additional 12,147 shares in the last quarter. Artisan Partners Limited Partnership increased its stake in NeoGenomics by 0.7% in the second quarter. Artisan Partners Limited Partnership now owns 2,175,072 shares of the medical research company’s stock valued at $28,515,000 after purchasing an additional 14,583 shares in the last quarter. Kopp Investment Advisors LLC increased its stake in NeoGenomics by 9.9% in the second quarter. Kopp Investment Advisors LLC now owns 436,972 shares of the medical research company’s stock valued at $5,729,000 after purchasing an additional 39,495 shares in the last quarter. Finally, Emerald Advisers Inc. PA increased its stake in NeoGenomics by 8.6% in the second quarter. Emerald Advisers Inc. PA now owns 1,374,446 shares of the medical research company’s stock valued at $18,019,000 after purchasing an additional 108,899 shares in the last quarter. 81.54% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ:NEO traded down $0.52 during mid-day trading on Friday, reaching $17.98. 1,143,384 shares of the company’s stock were exchanged, compared to its average volume of 797,033. The firm has a market cap of $1.47 billion, a PE ratio of 138.31 and a beta of -0.01. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.59 and a current ratio of 1.74. NeoGenomics has a twelve month low of $7.08 and a twelve month high of $19.04.

NeoGenomics (NASDAQ:NEO) last released its earnings results on Tuesday, October 30th. The medical research company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.03. The business had revenue of $69.10 million for the quarter, compared to analyst estimates of $66.13 million. NeoGenomics had a net margin of 1.70% and a return on equity of 3.15%. NeoGenomics’s revenue for the quarter was up 16.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.01 earnings per share. Sell-side analysts forecast that NeoGenomics will post 0.11 EPS for the current year.

About NeoGenomics

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories.

Recommended Story: How is Preferred Stock Different from Common Stock?

Analyst Recommendations for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply